Ymir and Knight Cancer Institute partner to develop HCC biomarkers

Ymir Genomics LLC (Cambridge, Mass.) and the Knight Cancer Institute at Oregon Health & Science University (Portland, Ore.) partnered to develop urinary biomarkers to detect hepatocellular carcinoma (HCC) in at-risk populations. Financial terms were not disclosed.

Ymir will isolate extracellular vesicles and analyze miRNA profiles of urine samples from liver cancer patients and high-risk cirrhotic patient controls provided by OHSU. OHSU will determine the vesicle preparations' protein profiles...